Piperidines
Medchemexpress LLC Nelfinavir Mesylate (AG 1343 Mesylate) | 159989-65-8 | C33H49N3O7S2 | 50 MG
Nelfinavir Mesylate is a potent, orally bioavailable inhibitor of HIV-1 protease (Ki=2 nM) used in the treatment of HIV infection. It also acts as a broad-spectrum anticancer agent.
- Potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) for HIV infection.
- Functions as a broad-spectrum anticancer agent.
- Inhibits the proliferation of multiple myeloma cells in a dose-dependent manner (IC50 of 1-5 μM).
- Impairs 26S chymotrypsin-like proteasome activity.
- Triggers apoptosis in myeloma cell lines and fresh plasma cells.
- Decreases the phosphorylation of AKT, STAT-3, and ERK1/2, and activates the pro-apoptotic pathway of the unfolded protein response system.
- Also identified as a SARS-CoV 3CLpro inhibitor with an IC50 of 35.93 μM.
Medchemexpress LLC Gemigliptin tartrate | 1374639-74-3 | 99.5% | 639.45 | 100 MG
Gemigliptin tartrate is a highly selective, reversible, and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor. It possesses potent anti-glycation properties and is suitable for research into advanced glycation end products (AGE)-related diabetic complications.
- Highly selective, reversible, and competitive DPP-4 inhibitor
- IC50 of 10.3 nM for human recombinant DPP-4
- Exhibits potent anti-glycation properties
- Inhibits formation of AGE-BSA
- Suppresses cross-linking of preformed AGE-BSA
- Inhibits AGEs formation and AGE cross-links in vivo
Medchemexpress LLC Gemigliptin tartrate | 1374639-74-3 | 99.5% | 639.45 | 50 MG
Gemigliptin tartrate is a highly selective, reversible, and competitive dipeptidyl peptidase-4 (DPP-4) inhibitor with an IC50 of 10.3 nM for human recombinant DPP-4. It exhibits potent anti-glycation properties and can be utilized for research into advanced glycation end products (AGE)-related diabetic complications.
- Highly selective, reversible, and competitive DPP-4 inhibitor
- Exhibits potent anti-glycation properties
- Can be used for research into advanced glycation end products (AGE)-related diabetic complications
- Inhibits the formation of AGE-BSA
- Suppresses the cross-linking of preformed AGE-BSA
- Dose-dependently inhibits plasma DPP-4 activity in rats, dogs, and monkeys
- Significantly reduces circulating AGE levels in serum in vivo
Medchemexpress LLC Nelfinavir mesylate | 159989-65-8 | C33H49N3O7S2 | 1 ML
Nelfinavir mesylate (AG 1343 Mesylate) is a potent and orally bioavailable HIV-1 protease inhibitor (Ki=2 nM) used for HIV infection. It also acts as a broad-spectrum anticancer agent.
- Potent HIV-1 protease inhibitor (Ki=2 nM)
- Broad-spectrum anticancer agent
- Inhibits proliferation of multiple myeloma cells
- Triggers apoptosis in myeloma cell lines
- Decreases phosphorylation of AKT
- Activates cleavage of caspase-3
- SARS-CoV 3CLpro inhibitor (IC50 = 35.93 μM)
Medchemexpress LLC Nelfinavir mesylate | 159989-65-8 | C33H49N3O7S2 | 25 MG
Nelfinavir Mesylate, also known as AG 1343 Mesylate, is a potent and orally bioavailable HIV-1 protease inhibitor. It is also described as a broad-spectrum anticancer agent and an inhibitor of SARS-CoV 3CLpro.
- Potent HIV-1 protease inhibitor (Ki=2 nM)
- Inhibits proliferation of multiple myeloma cells (IC50 of 1-5 μM)
- Triggers apoptosis of myeloma cell lines
- Decreases phosphorylation of AKT, STAT-3, ERK1/2
- Activates the pro-apoptotic pathway of the unfolded protein response system
- Inhibits SARS-CoV 3CLpro (IC50 of 35.93 μM)
- Decreases multiple myeloma cell growth in animal models